Observational studyPloS one2019
Prevalence and predictors for sustained remission in rheumatoid arthritis.
Observational study in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Restricted cubic spline analysis of treatment duration before tocilizumab withdrawal and relapse risk in rheumatoid arthritis.Therapeutic advances in musculoskeletal disease · 2026Article
- Extracellular vesicle-mediated immune crosstalk in rheumatoid arthritis synovium: mechanistic insights and translational challenges.Frontiers in immunology · 2026Review
- Predictors of Boolean2.0 remission in rheumatoid arthritis identified using smart disease management system data.Scientific reports · 2025Observational
- The High Prevalence of Sarcopenia in Rheumatoid Arthritis in the Korean Population: A Nationwide Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2023Article
- Prevalence and Predictors of Remission and Sustained Remission in Patients with Rheumatoid Arthritis from the United Arab Emirates: A Two-Year Prospective Study.Open access rheumatology : research and reviews · 2023Article
- Time-Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk.ACR open rheumatology · 2022Article
- Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China.Internal and emergency medicine · 2022Article
- [Innovative strategies for treatment of rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2022Review
- Analysis of the Associations between Arthritis and Fall Histories in Korean Adults.International journal of environmental research and public health · 2021Article
- Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis.Therapeutic advances in musculoskeletal disease · 2021Article
- Predictors and the optimal duration of sustained remission in rheumatoid arthritis.Clinical rheumatology · 2019Observational
- Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 6 institutions in 3 countries.
Funding
Abstract
objectiveRemission is a key goal in managing rheumatoid arthritis (RA), with sustained remission as the preferred sequelae of short-term remission. However little is known about the predictors of sustained remission for patients reaching remission. Using two independent cohorts, we aimed to evaluate the prevalence and predictors for sustained remission.
methodsThe study cohort consisted of subjects with RA from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) and the Korean Observational Study Network for Arthritis (KORONA). We analyzed subjects who reached remission in 2009 with follow up data for two consecutive years. Remission was defined by the Disease Activity Score 28- (DAS28-CRP) of less than 2.6. Sustained remission was defined as three consecutive annual visits in remission. Predictors for sustained remission were identified by multivariate logistic regression analysis.
resultsA total of 465 subjects were in remission in 2009. Sustained remission was achieved by 53 of 92 (57.5%) in BRASS and by 198 of 373 (53.1%) in KORONA. In multivariate analyses, baseline predictors of sustained remission were: disease duration less than 5 years [odds ratio (OR) 1.96, 95% confidence interval (95% CI) 1.08-3.58], Modified Health Assessment Questionnaire (MHAQ) score of 0 (OR 1.80, 95% CI 1.18-2.74), and non-use of oral glucocorticoid (OR 1.58, 95% CI 1.01-2.47).
conclusionMore than half of RA subjects in remission in 2009 remained in remission through 2011. Short disease duration, no disability, and non-use of oral glucocorticoid at baseline were associated with sustained remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.